Recent Analysts’ Ratings Updates for Medline (MDLN)

Several brokerages have updated their recommendations and price targets on shares of Medline (NASDAQ: MDLN) in the last few weeks:

• 11/7/2026 – Medline was upgraded by Wall Street Zen from “hold” to “buy”.
• 11/5/2026 – Medline had its price target raised by UBS Group from $43.00 to $49.00. They now have a “buy” rating on the stock.
• 11/5/2026 – Medline had its price target raised by Citigroup from $45.00 to $47.00. They now have a “buy” rating on the stock.
• 11/5/2026 – Medline had its price target raised by Leerink Partners from $43.00 to $46.00. They now have an “outperform” rating on the stock.
• 11/5/2026 – Medline had its “buy” rating reaffirmed by BTIG Research. They now have a $55.00 price target on the stock.
• 10/22/2026 – Medline had its price target lowered by Mizuho from $48.00 to $45.00. They now have an “outperform” rating on the stock.
• 10/20/2026 – Medline was downgraded by Zacks Research from “hold” to “strong sell”.
• 10/9/2026 – Medline had its price target lowered by Barclays from $45.00 to $43.00. They now have an “overweight” rating on the stock.
• 10/8/2026 – Medline was downgraded by Weiss Ratings from “sell (d+)” to “sell (d)”.
• 9/25/2026 – Medline had its price target lowered by UBS Group from $45.00 to $43.00. They now have a “buy” rating on the stock.
• 9/23/2026 – Medline had its “outperform” rating reaffirmed by William Blair.

Medline Stock Performance

Shares of Medline stock traded down $0.14 on Tuesday, hitting $40.57. The stock had a trading volume of 1,641,662 shares, compared to its average volume of 7,754,110. The stock has a market cap of $53.34 billion and a price-to-earnings ratio of 92.22. Medline has a 52-week low of $31.37 and a 52-week high of $50.88. The company’s 50 day moving average price is $34.89 and its 200 day moving average price is $39.47. The company has a current ratio of 4.33, a quick ratio of 2.61 and a debt-to-equity ratio of 0.66.

Medline (NASDAQ:MDLN) last released its quarterly earnings data on Wednesday, November 4th. The company reported $0.44 EPS for the quarter, topping analysts’ consensus estimates of $0.32 by $0.12. The firm had revenue of $7.86 billion for the quarter. Medline had a net margin of 1.84% and a return on equity of 8.22%. On average, research analysts anticipate that Medline will post 1.50 EPS for the current year.

Insider Buying and Selling

In related news, major shareholder Private Ltd Gic sold 2,088,987 shares of Medline stock in a transaction on Tuesday, October 6th. The stock was sold at an average price of $35.05, for a total transaction of $73,218,994.35. Following the completion of the sale, the insider owned 16,453,806 shares of the company’s stock, valued at approximately $576,705,900.30. This trade represents a 11.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In the last 90 days, insiders sold 7,948,676 shares of company stock valued at $281,805,137. 0.81% of the stock is owned by company insiders.

Medline is a healthcare products manufacturer and distributor serving providers across the care continuum. Its customers include hospitals, surgery centers, physician practices, long-term care facilities and home-care organizations.

The company offers a broad range of medical and surgical supplies, including products for infection prevention, wound care and patient care, as well as apparel and equipment. Medline also provides supply-chain and logistics services to healthcare organizations.

Founded in 1966, Medline is headquartered in Northfield, Illinois, and serves customers in the United States and internationally.